This article describes the results of recent study published in the JAMA Internal Medicine. It explores a fairly common side effect of some cancer treaments, “chemotherapy-induced peripheral neuropathy,” or CIPN. More than just an annoying condition, CIPN can have a significant effect on the quality of life for survivors. The study presented here offers some exciting news about possible treatments for this condition.
Oncologists and researchers increasingly focus on how to predict, treat and monitor for cardiovascular problems that develop before and after treatment.
Many women who are long-term Hodgkin’s survivors experience early menopause as a result of their radiation and chemotherapy treatments, especially if they received them at a young age. As we are already at risk for breast cancer due to the same treatments, it is important to be aware of any additional risk factors.
This week’s Joy Beat honoree is proof that even in the darkest of times, when life throws you its biggest challenges, there are people who can turn moments of adversity into joy. Erin Cummings joined GBH’s All Things Considered host Arun Rath to discuss her organization and how it has helped cancer survivors find community.
12News (KPNX-TV, NBC) features survivor, Dorothy Lynn Boddy and Hodgkin’s International.
Interesting study from the St. Jude Lifetime Cohort (SJLIFE), and originally published int the Journal of Clinical Oncology. The results may not be surprising, but it does appear that a plant-based diet has even more significance for childhood cancer survivors when it comes to premature aging and other health factors. (Note: the term “childhood cancer survivors” may include young adults in their 20’s).
This article describes research done by the Childhood Cancer Survivor Study of St. Jude Children’s Research Hospital and CARDIA, which stands for “Coronary Artery Risk Development in Young Adults.” These two organizations combined their data bases to create an in-depth study of the specific risks for childhood cancer survivors. The results are concerning, and they underline the need for early and frequent observation post treatment.
Hodgkin’s International was honored to be mentioned in this recent article about late effects that appeared in “Cancer Today,” a publication of the American Association for Cancer Research.
The research was presented in October, 2022 at the International Symposium on Hodgkin Lymphoma and earlier, at the ASCO (American Society for Clinical Oncology) Annual Meeting in 2021. A common chemotherapy drug used to treat Hodgkin lymphoma conferred a significantly increased risk of breast cancer among women treated during adolescence and adulthood, a large retrospective study showed.